Effectiveness of malic acid 1% in patients with xerostomia induced by antihypertensive drugs

Assessing the clinical effectiveness of a topical sialogogue on spray (malic acid, 1%) in the treatment of xerostomia induced by antihypertensive drugs. Study Design: This research has been carried out through a randomized double-blind clinical trial. 45 patients suffering from hypertensive drugs-induced xerostomia were divided into 2 groups: the first group (25 patients) received a topical sialogogue on spray (malic acid, 1%) whereas the second group (20 patients) received a placebo. Both of them were administered on demand for 2 weeks. Dry Mouth Questionnaire (DMQ) was used in order to evaluate xerostomia levels before and after product/placebo application. Unstimulated and stimulated salivary flows rates, before and after application, were measured. All the statistical analyses were performed by using SPSS software v17.0. Different DMQ scores at the earliest and final stage of the trial were analysed by using Mann-Whitney U test, whereas Student's T-test was used to analyse salivary flows. Critical p-value was established at p0.05) after placebo application. After two weeks of treatment with malic acid, unstimulated salivary flow increased from 0.17 to 0.242 mL/min whereas the stimulated one increased from 0.66 to 0.92 mL/min (p0.05). Conclusions: Malic acid 1% spray improved antihypertensive-induced xerostomia and stimulated the production of saliva

Dabigatran and rivaroxaban, new oral anticoagulants. New approaches in Dentistry

Treatment in patients with atrial fibrillation or venous thromboembolism in recent decades has been based almost exclusively on the use of vitamin K antagonists. These drugs have a narrow therapeutic index, so it is precise to repeated adjustments of doses that require analytical monitoring. For many years it has advocated the need to have more convenient new antithrombotic drugs. So is developing a new generation of antithrombotic not related to coumarin. In 2008 and 2009, two of these new anticoagulants have been registered and approved in Europe and Ca- nada-these are dabigatran etexilate (Pradaxa ®) and rivaroxaban (Xarelto ®). Anticoagulant dabigatran is the first direct thrombin inhibitor, orally available. Specifically and reversibly inhibits thrombin, so the duration of action is predictable. The anticoagulant effect correlates well with plasma drug concentrations, which implies an effective anticoagulation with low bleeding risk without major problems of interactions with other drugs. Rivaroxaban is first oral anticoagulant inhibitor of factor Xa (FXa). It produces a predictable and reversible inhibition of FXa activity with ability to inhibit clot-bound FXa. The predictable pharmacokinetics and pharmacodynamics characteristics of dabigatran and rivaroxaban may facilitate dental management of patients who until now have been in treatment with traditional anticoagulants, given that it doesn’t require routine laboratory monitoring in the vast majority of patients treated. They also present a profile of drug interactions very favourable

Guia per treballar i avaluar les competències generals de la UAB

Data d'actualització: abril de 2021La UAB va encetar fa un parell d'anys un projecte de revisió de les competències generals que haurien d'incloure tots els seus estudis de grau amb aquesta idea d'adaptar els estudis a la realitat canviant de la societat. L'objectiu d'aquesta guia és dotar la institució, i especialment aquelles persones directament relacionades amb el disseny i la millora de la qualitat de les titulacions de grau de la UAB, d'un marc i d'unes eines per adaptar els graus als nous requeriments de la societat a través de les competències generals que s'han redefinit

Ciencia Odontológica 2.0

Libro que muestra avances de la Investigación Odontológica en MéxicoEs para los integrantes de la Red de Investigación en Estomatología (RIE) una enorme alegría presentar el segundo de una serie de 6 libros sobre casos clínicos, revisiones de la literatura e investigaciones. La RIE está integrada por cuerpos académicos de la UAEH, UAEM, UAC y UdeG

Eficacia del ácido málico 1% en spray en pacientes con xerostomia inducida por antihipertensivos

Tesis Univ. Granada. Programa Oficial de Doctorado en: Medicina Clínica y Salud PúblicaEste trabajo ha sido financiado a través de: proyecto FIS PI10/00932 del Ministerio de Ciencia e Innovación, Instituto Carlos III; contrato OTRI CNT-2856, Universidad de Granada-Dentaid S.L. (Barcelona); grupo de investigación CTS-654 de la Junta de Andalucía